CaNCURE: Cancer Nanomedicine Co-ops For Undergraduate Research Experiences
CaNCURE:癌症纳米医学本科生研究经验合作社
基本信息
- 批准号:8742115
- 负责人:
- 金额:$ 23.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-18 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAntineoplastic AgentsAreaBiologyBiomedical ResearchCancer CenterCollaborationsCommitCommunitiesCritical ThinkingDevelopmentDiagnosticDiseaseEducationEngineeringEnsureEnvironmentEvaluationFundingFutureGoalsHealthHealthcareHome environmentHospitalsHuman ResourcesImageInternshipsJournalsKnowledgeMagnetic Resonance ImagingMalignant NeoplasmsMedicineMentorsMinority GroupsModelingMonitorNanotechnologyParticipantPathway interactionsPhysiciansPositron-Emission TomographyPreparationProceduresRadiation OncologyResearchResearch InfrastructureResearch PersonnelResearch Project GrantsScienceScientistSiteSmall Interfering RNAStudentsSystemTechniquesTechnologyTherapeuticTraineeshipTrainingTranslatingTravelUnderrepresented MinorityUniversitiesVisionWorkplaceanticancer researchcancer diagnosiscancer therapycareerclinical practicecultural competenceexperiencefight againstinterestmedical schoolsmeetingsmembernanomedicinenext generationnoveloptical sensorprogramspublic health relevanceskillssuccesssymposiumtargeted deliverytheranosticstumorundergraduate research
项目摘要
DESCRIPTION (provided by applicant): Nanotechnology has opened up a new, previously unimaginable world in cancer diagnosis and therapy, leading to an emerging paradigm, Cancer Nanomedicine. Northeastern University (NEU) and Dana Farber / Harvard Cancer Center (DF/HCC) propose to establish the CaNCURE program to train the next generation of scientists, technologists and physicians skilled in research at the interface of nanotechnology, biology and medicine. The CaNCURE program will address the need to translate the rapid and ongoing developments in cancer nanomedicine to academic programs that will attract and retain young scientists and engineers, particularly from underrepresented minority (URM) groups, and will encourage them to pursue higher education and careers in cancer research. The CaNCURE program will support academic year B.S. traineeships (105 over 5 years) along the lines of the cooperative education model pioneered by Northeastern University. The program will achieve its goals through the following specific aims: Specific Aim 1: Provide a hands-on research experience with a focus on cancer nanomedicine through an academic year co-op internship mentored by world-class cancer researchers and clinicians at NEU and DF/HCC. The internship will develop the trainee's research skills, expand critical thinking abilities, develop team-participation and collaboration skills, and facilitate the trainee's ability to do independent research safely and responsibly. Specific Aim 2: Develop a set of activities for year- round education, including a bi-monthly seminar, a journal club, and conference travel opportunities that will increase participants' knowledge of cancer nanomedicine. Specific Aim 3: Develop students' knowledge of health and biomedical research careers and the preparation needed to attain them, thus creating a pipeline of students interested in cancer and cancer nanomedicine careers. Specific Aim 4: Increase the diversity of the cancer research workforce by targeted recruitment and retention programs. We anticipate that the majority of CaNCURE trainees will be members of groups which are underrepresented in the biomedical sciences. Their cultural competence will enhance their ability to contribute to the reduction of health care disparities. Northeastern University is a recognized leader in cooperative experiential education. NEU's unique co- op model, which has been developed over the last 100 years, integrates 2 or 3 six-month practical experiences in a research or workplace environment. The partnership between Northeastern University and the Dana Farber / Harvard Cancer Center, which is comprised of 7 research hospitals in the Harvard Medical School system, brings together more than 1000 cancer researchers. 35 outstanding researchers have committed to mentor and train CaNCURE trainees. We will capitalize on this access to develop interdisciplinary cancer scientists, technologists and physicians for the 21st Century cancer workforce.
描述(由申请人提供):纳米技术开辟了一个新的,以前无法想象的世界,在癌症诊断和治疗,导致一个新兴的范例,癌症纳米医学。东北大学(NEU)和达纳法伯/哈佛癌症中心(DF/HCC)建议建立CaNCURE计划,以培养下一代科学家,技术人员和医生在纳米技术,生物学和医学的接口研究熟练。CaNCURE计划将满足将癌症纳米医学的快速和持续发展转化为学术计划的需要,这些计划将吸引和留住年轻的科学家和工程师,特别是来自代表性不足的少数民族(URM)群体的科学家和工程师,并将鼓励他们接受高等教育和从事癌症研究。 CaNCURE计划将支持学年B.S.沿着东北大学开创的合作教育模式的路线进行培训(5年内105人)。该计划将通过以下具体目标实现其目标:具体目标1:通过由NEU和DF/HCC的世界级癌症研究人员和临床医生指导的学年合作实习,提供专注于癌症纳米医学的实践研究经验。实习将培养学员的研究技能,扩大批判性思维能力,培养团队参与和协作技能,并促进学员安全和负责任地进行独立研究的能力。具体目标二:开发一系列全年教育活动,包括双月研讨会,期刊俱乐部和会议旅行机会,这将增加参与者对癌症纳米医学的知识。具体目标3:发展学生的健康和生物医学研究事业的知识和实现它们所需的准备,从而创造了对癌症和癌症纳米医学事业感兴趣的学生的管道。具体目标4:通过有针对性的招聘和保留计划增加癌症研究人员的多样性。我们预计,大多数CaNCURE学员将是在生物医学科学代表性不足的群体的成员。他们的文化能力将提高他们为减少保健差距作出贡献的能力。 东北大学是公认的合作体验教育的领导者。NEU独特的合作模式,已经发展了100多年,在研究或工作环境中整合了2或3个六个月的实践经验。东北大学和Dana Farber /哈佛癌症中心之间的合作伙伴关系,由哈佛医学院系统的7家研究医院组成,汇集了1000多名癌症研究人员。35位杰出的研究人员致力于指导和培训CaNCURE学员。我们将利用这一机会,为21世纪世纪的癌症工作者培养跨学科的癌症科学家、技术专家和医生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SRINIVAS SRIDHAR其他文献
SRINIVAS SRIDHAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SRINIVAS SRIDHAR', 18)}}的其他基金
Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy
用于放化疗的药物洗脱近距离放射治疗植入物
- 批准号:
9908977 - 财政年份:2017
- 资助金额:
$ 23.27万 - 项目类别:
Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy
用于放化疗的药物洗脱近距离放射治疗植入物
- 批准号:
10017919 - 财政年份:2017
- 资助金额:
$ 23.27万 - 项目类别:
Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy
用于放化疗的药物洗脱近距离放射治疗植入物
- 批准号:
9466175 - 财政年份:2017
- 资助金额:
$ 23.27万 - 项目类别:
CaNCURE: Cancer Nanomedicine Co-ops For Undergraduate Research Experiences
CaNCURE:癌症纳米医学本科生研究经验合作社
- 批准号:
9081554 - 财政年份:2014
- 资助金额:
$ 23.27万 - 项目类别:
CaNCURE: Cancer Nanomedicine Co-ops For Undergraduate Research Experiences
CaNCURE:癌症纳米医学本科生研究经验合作社
- 批准号:
9304985 - 财政年份:2014
- 资助金额:
$ 23.27万 - 项目类别:
CaNCURE: Cancer Nanomedicine Co-ops for Undergraduate Research Experiences
CaNCURE:癌症纳米医学本科生研究经验合作社
- 批准号:
10675069 - 财政年份:2014
- 资助金额:
$ 23.27万 - 项目类别:
CaNCURE: Cancer Nanomedicine Co-ops for Undergraduate Research Experiences
CaNCURE:癌症纳米医学本科生研究经验合作社
- 批准号:
10441281 - 财政年份:2014
- 资助金额:
$ 23.27万 - 项目类别:
CaNCURE: Cancer Nanomedicine Co-ops for Undergraduate Research Experiences
CaNCURE:癌症纳米医学本科生研究经验合作社
- 批准号:
10206035 - 财政年份:2014
- 资助金额:
$ 23.27万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 23.27万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 23.27万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 23.27万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 23.27万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 23.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 23.27万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 23.27万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 23.27万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 23.27万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 23.27万 - 项目类别:














{{item.name}}会员




